Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
MK-677 (Ibutamoren) (MK677) is a growth hormone peptide, at the clinical trials stage in the published literature. Orally active growth hormone secretagogue that mimics ghrelin, providing 24-hour GH elevation without injections.
Orally active growth hormone secretagogue that mimics ghrelin, providing 24-hour GH elevation without injections.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 24 hours |
| Administration | Oral |
| Doses Reported in Published Studies | 10-25 mg oral |
Non-peptide ghrelin mimetic that activates ghrelin receptors orally, causing sustained GH and IGF-1 elevation.
Orally active growth hormone secretagogue that mimics ghrelin, providing 24-hour GH elevation without injections.
Non-peptide ghrelin mimetic that activates ghrelin receptors orally, causing sustained GH and IGF-1 elevation.
MK-677 (Ibutamoren) is at the following stage in the published literature: Clinical trials. All information is for research and educational purposes only.
Reported half-life: 24 hours.
Reported administration route in the literature: Oral. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.